AI assistant
ROCKET PHARMACEUTICALS, INC. — Director's Dealing 2024
Feb 16, 2024
33148_dirs_2024-02-16_eb454137-fdfc-4f4b-a002-445737e70c6f.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: ROCKET PHARMACEUTICALS, INC. (RCKT)
CIK: 0001281895
Period of Report: 2024-02-14
Reporting Person: Militello John (N/A)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2024-02-14 | Common Stock | M | 6274 | — | Acquired | 16433 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2024-02-14 | Restricted Stock Units | $ | M | 725 | Disposed | Common Stock (725) | Direct | |
| 2024-02-14 | Restricted Stock Units | $ | M | 5549 | Disposed | Common Stock (5549) | Direct |
Footnotes
F1: Represents shares of Common Stock received upon vesting of a restricted stock unit ("RSU") award.
F2: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.
F3: One-third (1/3) of such RSUs became fully vested and exercisable on February 14, 2023, with the remaining shares vesting in equal quarterly installments over the following two years.
F4: One-third (1/3) of such RSUs became fully vested and exercisable on February 14, 2024, with the remaining shares vesting in equal quarterly installments over the following two years.